Peptide triple agoniste de nouvelle génération.
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This innovative approach aims to maximize metabolic benefits through activation of three complementary pathways.
Key Research Areas:
• Maximum weight loss potential
• Enhanced glucagon-mediated lipolysis
• Improved glucose homeostasis
• Energy expenditure increase
• Metabolic disease treatment
Early clinical data suggests retatrutide may produce the most significant weight loss of any incretin-based therapy studied to date.
RESEARCH USE ONLY: All products sold on this website are intended for laboratory and research purposes only. These products are NOT intended for human or animal consumption.
